Personalized treatment for cancer with genetic fingerprints
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57
 
Personalizing cancer treatment with genetic fingerprint

Not all cancers are equally lethal: cancer in your prostate means a longer survival rate than a malignancy in your brain, for example. But even prostate cancer comes in multiple flavors ranging from manageable to very bad. By analyzing the mutated genome of a tumor, doctors can now pinpoint whether a cancer is sensitive to a certain chemotherapy, or one that doesn’t respond at all to current treatments. Knowing the subtype might mean jumping directly to a clinical trial that could save your life.

Cancer is a disease of the genome. It arises when genes involved in promoting or suppressing cell growth sustain mutations that disturb the normal stop and go signals. There are more than 100 different types of cancer, most of which derive their names and current treatment based on their tissue of origin—breast, colon, or brain, for example. But because of advances in DNA sequencing and analysis, that soon may be about to change.

A new method to take the DNA fingerprint of individual cancer cells is uncovering the true extent of cancer’s genetic diversity. A single cancer cell may help oncologists anticipate tumor growth. A genetic “fingerprint” taken from a cancerous cell can reveal the extent of the cancer’s genetic diversity — its “family tree.” By highlighting key mutations, the method could help doctors develop more effective, personalized therapies.

There is a huge potential to identify key genomic changes shared by certain subsets of tumors, regardless of where they arise in the body. Such information is vital to our efforts to develop more individualized approaches for helping people with cancer—called personalized medicine, or precision medicine. For example, if a patient’s tumor has a genomic fingerprint that indicates it is likely to spread to other areas of the body, or metastasize, doctors may suggest a more aggressive treatment strategy than they would for someone whose tumor had a different profile.

Genomic information might also help us figure out if a drug originally approved for use in one type of cancer might be useful in treating other types. For example, if a drug works for colon cancer, it might also work for a lung cancer with a similar genetic fingerprint.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
nutrition
oncology
prevention
dermatology
cancer
Anti-aging
age management
detoxification
skin
diagnosis
heavy metal
cardiology
immunology
liver detox
oncology treatment
DNA
pain
Genetics
stem cells
allergy
Fertility
weight management
infertility
weight loss
liver
cosmetology
gastroenterology
Sleep
gynecology
Examination partner centres
rehabilitation
chelation
obstetrics
pregnancy
headache
check-up
anti-aging
candida
radiology
immune system
neurology
urology
arsenic
breast cancer
immunotherapy
probiotics
NAD+
mesotherapy
Apnea
tinnitus
Дерматология
joints
Hepatitis C
heart MRI
covid19
Blood pressure
skincare
ulcer
research
abdominal pain
sugar
menopause
migraine
beau-rivage
hyaluronic acid
Allergology
pancreas
gastritis
flu vaccine
gastroscopy
rhesus factor
preventiion
brain surgery awake
andropause
sexuality
obstertics
PRP
light therapy
nutrigenomics
excimer laser
psoriasis
regeneration
telomere
mastectomy
narcosis
hand
shoulder
intestinal flora
depression
second opinion
iron
Omega-3
R-loops
cellmen
mammography
cellcosmet
herniated disc
magnesium
flu
reflexology
vitamin K
exercise
beauty
sports
cholesterol
Treatment programs
stress
knee
hip
vitamin b12
food
mercury
water
back pain
erectile dysfunction
food intolerances
diabetes
acne
endometriosis
LED therapy
biopsy
oral checkup
liquid biopsy
blood test
reconstruction
acnea
digestion
migraines
chronic headaches
oncoloy
diet
dermatitis
endocrinology
rheumatology
pomegranate
orthopedics
colonoscopy
propofole
cellulite
proctology
pneumology
general surgery
hormones
nephrology
kidney
lungs
plastic surgery
ophthalmology